Kimani Francis T, Thiongó Kelvin K, Otinga Maureen A, Mbabu Lewis K, Ombati Mary N, Kitur Stanley K, Ochieng' Sarah A, Wachira Lucy N, Matoke-Muhia Damaris K, Kamau Luna
Centre for Biotechnology Research and Development, Kenya Medical Research Institute (KEMRI), Nairobi, Kenya.
Malar J. 2025 Jan 13;24(1):10. doi: 10.1186/s12936-024-05214-4.
The current study sought to re-evaluate malaria prevalence, susceptibility to artemisinin-based combination therapy (ACT), transmission patterns and the presence of malaria vectors in the Kikuyu area of the Kenyan Central highlands, a non-traditional/low risk malaria transmission zone where there have been anecdotal reports of emerging malaria infections.
Sampling of adult mosquitoes was done indoors, while larvae were sampled outdoors in June 2019. The malaria clinical study was an open label non-randomized clinical trial where the efficacy of one ACT drug, was evaluated in two health facilities. Microscopy was used at the facility while nested 18 s rRNA subunit gene PCR amplification and MSP-1 and MSP-2 family alleles genotyping was done in the laboratory. Anti-malarial resistance gene markers Pfk13 and Pfmdr1 were profiled.
Anopheles funestus mosquitoes were the predominant vectors at 76.35% of all larvae collections (N = 148). Only two non-blood fed, parasites negative adult mosquitoes were collected from houses sampled. Parasitological analysis of the 838 patients screened resulted in 41 positives whose treatment outcome was 100% Adequate Clinical and Parasitological Response (ACPR). From the 35 positive samples genotyped, 29 (82.9%) were polyclonal. The overall mean MOI was 2.8 (95% CI 2.36-3.35). The MOI for msp-1 and msp-2 genes, was 2.02 (95% CI 0.72-2.27) and 2.9 (95% CI 2.22-3.55), and parasite strains range of 1-3 and 1-7, respectively. Polyclonal variation in the two genes was at 76.4% and 70.3%, respectively. The Pfk13 gene revealed no single nucleotide polymorphisms (SNP) associated with suspected artemisinin resistance nor was there any pfmdr1 N86 mutant allele detected.
The Plasmodium infections positivity rate observed in the study site was very low but significant. A proportion of participants who tested positive did not report recent history of travel. This observation together with the finding of competent known vectors can probably suggest that several of the cases could have been acquired and transmitted locally. The observed genetic diversity and polyclonal variations was on the contrary and suggest that these are imported cases. This however does not rule out a likely changing malaria transmission scenario in this zone, thus the need for further investigations.
本研究旨在重新评估肯尼亚中部高地基库尤地区的疟疾流行率、对青蒿素联合疗法(ACT)的敏感性、传播模式以及疟蚊的存在情况。该地区是一个非传统/低风险疟疾传播区,有传闻称出现了新的疟疾感染病例。
2019年6月,在室内对成年蚊子进行采样,同时在室外对幼虫进行采样。疟疾临床研究是一项开放标签的非随机临床试验,在两个医疗机构评估了一种ACT药物的疗效。在医疗机构使用显微镜进行检测,同时在实验室进行巢式18 s rRNA亚基基因PCR扩增以及MSP-1和MSP-2家族等位基因基因分型。对抗疟抗性基因标记物Pfk13和Pfmdr1进行了分析。
在所有采集的幼虫中,76.35%的幼虫样本采集到了致倦库蚊,是主要的病媒(N = 148)。在采样房屋中仅采集到两只未吸血、寄生虫阴性的成年蚊子。对838名筛查患者进行的寄生虫学分析发现41例阳性,其治疗结果的充分临床和寄生虫学反应(ACPR)率为100%。在35份基因分型的阳性样本中,29份(82.9%)为多克隆。总体平均感染复数(MOI)为2.8(95%可信区间2.36 - 3.35)。msp-1和msp-2基因的MOI分别为2.02(95%可信区间0.72 - 2.27)和2.9(95%可信区间2.22 - 3.55),寄生虫株数范围分别为1 - 3和1 - 7。这两个基因的多克隆变异分别为76.4%和70.3%。Pfk13基因未发现与疑似青蒿素抗性相关的单核苷酸多态性(SNP),也未检测到任何pfmdr1 N86突变等位基因。
在研究地点观察到的疟原虫感染阳性率非常低,但具有统计学意义。一部分检测呈阳性的参与者没有报告近期的旅行史。这一观察结果以及发现有传播能力的已知病媒,可能表明其中一些病例可能是在当地感染和传播的。然而,观察到的基因多样性和多克隆变异情况则相反,表明这些是输入性病例。不过,这并不排除该地区疟疾传播情况可能发生变化,因此需要进一步调查。